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Insulin, a protein critical for metabolic homeostasis, provides
a classical model for protein design with application to human
health. Recent efforts to improve its pharmaceutical formula-
tion demonstrated that iodination of a conserved tyrosine
(TyrB26) enhances key properties of a rapid-acting clinical ana-
log. Moreover, the broad utility of halogens in medicinal chem-
istry has motivated the use of hybrid quantum- and molecular-
mechanical methods to study proteins. Here, we (i) undertook
quantitative atomistic simulations of 3-[iodo-TyrB26]insulin to
predict its structural features, and (ii) tested these predictions
by X-ray crystallography. Using an electrostatic model of the
modified aromatic ring based on quantum chemistry, the calcu-
lations suggested that the analog, as a dimer and hexamer,
exhibits subtle differences in aromatic-aromatic interactions at
the dimer interface. Aromatic rings (TyrB16, PheB24, PheB25, 3-I-
TyrB26, and their symmetry-related mates) at this interface
adjust to enable packing of the hydrophobic iodine atomswithin
the core of each monomer. Strikingly, these features were
observed in the crystal structure of a 3-[iodo-TyrB26]insulin ana-
log (determined as an R6 zinc hexamer). Given that residues
B24–B30 detach from the core on receptor binding, the envi-
ronment of 3-I-TyrB26 in a receptor complex must differ from
that in the free hormone. Based on the recent structure of a
“micro-receptor” complex, we predict that 3-I-TyrB26 engages
the receptor via directional halogen bonding and halogen-di-
rected hydrogen bonding as follows: favorable electrostatic
interactions exploiting, respectively, the halogen’s electron-de-
ficient -hole and electronegative equatorial band. Inspired by
quantum chemistry and molecular dynamics, such “halogen
engineering” promises to extend principles of medicinal chem-
istry to proteins.
Insulin, a small protein critical to metabolic homeostasis (1),
provides a model for studies of protein folding and design (2)
with long-standing application to human therapeutics (3). The
hormone contains two chains, A and B (Fig. 1A), linked by two
disulfide bridges (cystines A7–B7 andA20–B19); the A chain is
further stabilized by cystine A6–A11. In pancreatic -cells,
insulin is stored within the secretory granules as zinc-coordi-
nated hexamers. This study has exploited insulin semi-synthe-
sis (4) (simplified through the use of norleucine (Nle)9 at posi-
tion B29; arrow in Fig. 1A (5)) to investigate a site-specific
modification of an aromatic ring by a single halogen atom (6).
The modification, 3-iodo-Tyr at position B26 (3-I-TyrB26), is
associated with enhanced binding to the insulin receptor (IR)
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(7–9). The general class of halo-aromatic modifications defines
a key frontier of medicinal chemistry (10) and holds promise in
the non-standard engineering of proteins through manipula-
tion of  systems and weakly polar interactions (11, 12). In
addition, the -hole of larger halogens can anchor interactions
with surrounding polar groups and water molecules (13–19).
3-[iodo-TyrB26]Insulin thus provides a model for studies of
engineered proteins at the border of molecular mechanics and
quantum chemistry.
Crystal structures of insulin (as zinc-free dimers (20) or zinc-
stabilized hexamers (21–23)) provide a foundation for its ther-
apeutic formulation (24) and analysis of structure-activity rela-
tionships (2, 25, 26). The structure of a monomer in solution
(27–30) resembles a crystallographic protomer (as in zinc-free
T2 dimers or T6 zinc hexamers) (Fig. 1B); this “closed” confor-
mation contains an -helical globular subdomain and tethered
C-terminal B-chain -strand (residues B24–B28). TyrB26 (red
in Fig. 1A, asterisk) provides a key contact between the-strand
FIGURE 1. Insulin sequence and structure. A, sequence ofWT insulin andmodification sites. A and B chains are shown inwhite and gray. Conserved aromatic
residues PheB24 and PheB25 are highlighted as black circles. This study focused on substitutions of TyrB26 (red circle); additional substitutions were made at
position B29 (Nle; arrow) to facilitate semi-synthesis. B, ribbonmodel of insulin monomer (T state extracted from T6 zinc hexamer) (2). The A chain is shown in
yellow and the B chain in black (B1–B19) and green (B20-B30). C, environment of TyrB26 (stereo). The side chain of TyrB26 is highlighted in red; IleA2, ValA3, ValB12,
LeuB15, and PheB24 are as labeled. D, stick representation of residues B20–B27 (carbon atoms (green), nitrogen atoms (blue) and oxygen atoms (red)) packed
betweenCTand the L1-2 sheet. B chain residuesB8–B19are shownas ablack ribbon and theAchain as a yellow ribbon; residuesA1–A3are concealedbehind
the surface of CT. Key contact surfaces of CT with B24–B26 are highlighted inmagenta, and L1 with B24–B26 are highlighted in cyan; L1 and CT surfaces
not in interactionwith B24–B26 are shown in lighter shades. E, orthogonal view toD, showing interaction of the side chain of PheB24 with the nonpolar surface
of the L1-2 sheet. Tyr
B26 is hidden below the surface of CT. Engagement of conserved residues A1–A3 against the nonpolar surface of CT is shown at top.
F, environment of TyrB26within site 1 complex (stereo). Neighboring side chains in L1 andCT are as labeled. Coordinateswere obtained fromPDB code 4OGA
(39). G, model of wild-type insulin in its receptor-free conformation overlaid onto the structure of the insulin-bound IR (71). The L1 domain and part of CR
domainare shown inpowderblue;CT is shown inpurple. ResiduesPheB24 andTyrB26 areas inA. TheBchainofIR-bound insulin is shown indarkgray (B6–B19);
the brown tube indicates classical location within the overlay of residues B20–B30 of insulin in its receptor-free conformation, highlighting steric clash of
B26–B30withCT. In theIR co-crystal structure, insertion of the insulin B20–B27 segment between L1 andCT peptide is associatedwith a small rotation of
the B20–B23 -turn and changes in main-chain dihedral angles flanking PheB24 (39). H, inverted V-shaped assembly of IR ectodomain homodimer. One
monomer is in ribbon representation (labeled), the second in surface representation. Domains are labeled as follows: L1, first leucine-rich repeat domain; CR,
cysteine-rich domain; L2, second leucine-rich repeat domain; FnIII-1, -2, and -3, first, second, and third fibronectin type III domains, respectively; ID, insert
domain; and CT, -chain C-terminal segment. Coordinates were obtained from PDB code 4ZXB (42).
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and the -helical subdomain (Fig. 1C). The contribution of this
side chain to the stability of the insulin monomer has recently
been investigated by molecular dynamics (MD) simulations
(31) and mutagenesis (32).
Insulin undergoes a change in conformation to “open” on
receptor binding (33–37). A recent structural advance
exploited domain-minimized models of the -subunit of the
insulin receptor (IR) (38) containing the primary insulin-bind-
ing elements (leucine-rich domain 1 (L1) and the C-terminal
segment of the -subunit (CT)) (39). A co-crystal structure
has been determined at 3.5 Å resolution of a ternary complex
involving insulin, an L1-CR fragment, and a synthetic CT
peptide (residues 704–719 of receptor isoformA (IR-A)) (39).10
In this structure (designated the micro-receptor (IR) com-
plex), the C-terminal segment of the insulin B chain is detached
from the hormone’s-helical core; such detachment enables its
insertion between L1 and CT (Fig. 1D). The inserted segment
includes a conserved triplet of aromatic residues (PheB24,
PheB25, and TyrB26) that lie at the IR interface (39). Whereas
PheB24 packs within a classical nonpolar pocket, TyrB26 lies at
one edge (Fig. 1D and 90° rotated view in Fig. 1E). An expanded
view of the TyrB26 environment in the IR (Fig. 1F) highlights
contacts to conserved residues within L1 (Asp-12, Arg-14, and
His-32) and CT (Val-715). These contacts require reposition-
ing of the C-terminal segment of the insulin B chain from its
unbound conformation (green in Fig. 1G) in the IR complex
(black), thereby avoiding a clash between B25–B30 and CT
(purple). The L1 and CT elements of the ectodomain belong
to different -subunits within the multidomain ()2 IR dimer
(Fig. 1H). Binding of insulin in trans to these elementsmay alter
the orientation between the -subunits as the first step in
signal propagation (40–42).11
Insulin’s dimer interface is remarkable for aromatic-aro-
matic interactions across eight aromatic side chains (TyrB16,
PheB24, PheB25, TyrB26, and their symmetry-related mates (2,
43)). In this cluster, the side chain of TyrB26 packs against
PheB24 and the dimer-related side chains of TyrB16 and PheB24
(where  indicates that the residue belongs to the alternate
monomerwithin the dimer; Fig. 2A), giving rise to complex and
asymmetric electrostatic environments (44). Halogen substitu-
tions within these rings would be expected to alter the distribu-
tion of  electrons and so modulate such interactions (Fig. 2B).
In addition, the tyrosine’s para-OHgroupwould be expected to
cause subtle differences in iodine’s inductive effects (Fig. 2C).
Given these features, the present study focused on the effects of
iodination ofTyrB26, longknowntoenhance theaffinityof insulin
for the IR (7–9) and recently shown to enhance the pharmaceuti-
cal properties of a rapid-acting clinical analog, including its stabil-
ity and resistance to physical degradation (45).12 Such findings
raise salient questions regarding the role of the iodo-aro-
matic modification on the structure of the free hormone and
its potential role at the hormone-receptor interface.
How might iodination of an aromatic residue affect its elec-
trostatic properties and in turn its conformation? What would
be the preferredmolecular environment of the iodine, and how
might its quantum-chemical features be exploited? In particu-
lar, how might the asymmetric electronic distribution of the
iodo-substituent, in principle capable of halogen bonding (46,
47) and/or halogen-directed hydrogen bonding (18, 48, 49),
affect weakly polar interactions within the protein (44)? To
what extent might these chemical features underlie the
improved biochemical or biophysical properties of such amod-
ified protein?We addressed these questions in three parts. Our
study began with molecular dynamics (MD) simulations of
3-[iodo-TyrB26]insulin with multipolar parameters derived
from quantum-mechanical (QM) modeling of the halogenated
side chain. We next verified predicted features of such models
by determining the crystal structure of a 3-[iodo-TyrB26]insulin
analog, herein described as an R6 zinc insulin hexamer. The
final part of this study sought insight into potentialmechanisms
by which 3-I-TyrB26 enhances IR binding (7–9). Together, our
results highlight the promise of non-standard protein engineer-
ing guided bymolecular mechanics at the interface of quantum
chemistry.
Results
Rigid-bodyModeling Distinguished Opposite Edges of the B26
Aromatic Ring
Past 1HNMRstudies of insulin as anR6 zinc hexamer (50, 51)
or engineered T2 dimer (52) demonstrated that all Phe and Tyr
side chains exhibit equivalentmeta resonances (ring positions 3
and 5 as defined in Fig. 2A, left) and likewise equivalent ortho
resonances (positions 2 and 6). These observations indicated
that the aromatic rings either freely rotate (as do PheB1 and
TyrA14) or undergo rapid 180° “flips” about the C–C bond
axis (1 ms on the NMR time scale; TyrA19, TyrB16, PheB24,
PheB25, and TyrB26). Because within the native state the latter
rotations would incur steric clashes, such 1H NMR features
reflect the flexibility of the surrounding protein framework
(50).
Respective ortho andmeta positions of 3-I-Tyr are in princi-
ple not equivalent. Accordingly, which of the two B26 confor-
mations, i.e. with the iodine “in” or “out” with respect to the
core of a monomer, is preferred? In either orientation, the
iodine atomwould be inaccessible to solvent within a nonpolar
environment. Naive modeling of the insulin dimer suggested
that either conformationwould encountermarked steric occlu-
sion as follows: at the 3-position (in), an iodine would overlap
with the -CH3 of IleA2 and one -CH3 of ValA3 (Fig. 3A),
10 The respective mRNAs encoding isoforms A and B of the IR differ by the
absence (A) or presence (B) of 36 bases encoded by exon 11 (110).
11 Because hormone-ectodomain complexes have to date proven refractory
to crystallization, it is not known whether or how domains CR, L2, or the
three fibronectin-homology domainsmay contribute to insulin binding or
signaling (39). Potential structural differences between isoforms IR-A and
IR-B (110) are also not well understood.
12 Biophysical effects of the iodo-TyrB26modificationwere recently studied in
the context of insulin lispro (containing substitutions ProB28 3 Lys and
LysB293 Pro; the active component of Humalog (Lilly) (45). Although the
structure of the modified analog was not determined, iodo-TyrB26 was
found to mitigate the loss of stability associated with the paired B28–B29
substitutions. In the context of the present parent analog ([NleB29]insulin),
iodo-TyrB26 does not alter stability, presumably because the native Pro at
B28 is retained, i.e. the parent’s native-like dimer interface is not in need of
repair. The iodo-TyrB26modificationenhances receptorbinding to a similar
extent in both templates.
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whereas at the 5-position (out) it would encounter the side
chain of dimer-related TyrB16 and carbonyl oxygen of GlyB20
(Fig. 3B). The seeming steric incompatibility of either 3-I-
TyrB26 or 5-I-TyrB26 in naive models (akin to seeming steric
barriers to ring rotation) stood in contrast to its observed sta-
bilization of an insulin analog (5), suggesting that structural
FIGURE 2. Quantum chemistry of iodo-aromatic system. A, Tyr side chain with iodine in its 3- or 5-ring position (green and yellow, in and out, respectively)
with carbon-atom positions labeled. Rotation angles for rigid-body modeling involve rotations around the C–C bond (1) and C–C bond (2). The insulin
dimerwith B26 side chains (red) and side chains of TyrB16, PheB24, PheB25, and their dimer-relatedmates (blue). The right-hand sideprovides a cross-eyed stereo
viewof themodifieddimerwith the B chain helix removed for clarity.B, electrostatic potential (ESP) surfacemaps of phenol, iodophenol, and iodophenyl at the
0.001 e bohr3 isodensity. The color scale of the surface potential ranges from2.12 e2 (red) through 0 (green) to 2.12 e2 (blue). In the upper row the iodine
(facing the viewer) exhibits the effect of the electron-donating –OH on the -hole. The lower row shows effects of iodine on the -system of the phenol ring.
In the 1st row the surface is opaque, and in the 2nd row the surface is transparent. Angle represents the-hole size as delimited by black dashed lines. 	 and
	 represent respective regions of positive and negative charge around the iodine. C, ESP contours of iodophenyl (left) and 2-iodophenol (right), at different
isovalues, calculated in the plane of the aromatic ring. The halogen boundary represents a region of an electron isodensity of 103 e bohr3 (111). Isocontours
in the left and right panels are at the same heights but in uneven separations. The-hole size, defined by an angle (B), was calculated from the angular profile
of the ESP on the intersection line of the 2D grid and halogen boundary where the ESP changes its sign (55); positive ESP and negative ESP regions are shown
in blue and red, respectively. The black dashed arrow indicates directionality of the C–I bond.
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accommodation at one or the other sites is feasible and without
free-energy penalty.
To evaluate the two competing modes of iodo-Tyr packing,
we first explored potential local accommodation by consider-
ing B26 (1,2) energy maps in the neighborhood of the native
structure. Insight was obtained through the use of increasingly
realistic models as follows: first, a conventional point charge
(PC (53))model, and second, an improved representation based
on electrostatic multipoles (MTP (54)) as parameterized by ab
initio quantum-chemical calculations (see “Experimental Pro-
cedures”). We then explored potential interplay of local and
non-local mechanisms using MD simulations based on MTPs
for the modified side chain. The latter captured essential
aspects of quantum chemistry without incurring the compu-
tational burden of explicit mixed quantum mechanical/mo-
lecular mechanics (QM/MM) simulations. These results are
described in turn.
Residue-specific EnergyMaps Suggest Local Accommodation
Is Possible
For a given representation (PCorMTP) of theB26 side chain,
its conformation-dependent empirical energywas first assessed
within a rigid protein environment (“unrelaxed maps”). Subse-
quent energy minimization at each B26 (1,2) setting allowed
local structural reorganization of neighboring side chains,
yielding the corresponding “relaxed maps.” Comparison of
unrelaxed (Fig. 3, C and E) and relaxed (Fig. 3, D and F) maps
suggested that local steric clashes could be mitigated. Compar-
ison of respective PC- and MTP-based maps informed the
extent to which such mitigation is influenced by electrostatic
features of the iodo-aromatic system.
Representation of Residue B26 by a PC Model—A first step
toward distinguishing between “in” and “out” isomers was pro-
vided by rigid-body calculations assuming either 3-I-TyrB26
(green position in Fig. 2A) or 5-[iodo-TyrB26]insulin (yellow
position in Fig. 2A); in the context ofWT insulin, the 3-I and 5-I
isomers, respectively, correspond to “iodo-in” and “iodo-out”
conformations. To this end, unrelaxed (1,2) energy maps in
the neighborhood of the WT structure (15 in each dihedral
angle in steps of 1°) were computed using a conventional PC
representation for three B26 side chains (unmodified TyrB26,
3-I-TyrB26, and 5-I-TyrB26; left to right in Fig. 3C). This repre-
sentation neglected known anisotropic electrostatic features
around halogens (48) and their perturbation by the neighboring
para-OH group (Fig. 2C) (18, 55). The shared energy scale of
the 3-I and 5-I maps cannot be directly compared with that of
WT.
Despite the PC approximation, comparison of qualitative
features was informative. (a) Consistent with naive modeling,
violations (red regions in Fig. 3C) are more severe for the iodi-
nated residues than for the unmodified residue. (b) WT- and
5-I-TyrB26 maps are similar in overall topography; in each case
a hydrogen atom at the 3-position points toward the crowded
core of the same monomer. (c) Surprisingly, in this particular
“frozen” protein environment, 3-I-TyrB26 appears to be ener-
getically favored over 5-I-TyrB26. (d) Despite its lower mini-
mum, the 3-I basin is considerably narrower, especially with
respect to 1 rotation, than is the 5-I basin (or that of the
unmodified residue; Fig. 3C). The “walls” of this narrow basin
were enforced largely by steric clashes with neighboring side
chains (IleA2, ValA3, IleB11, ValB12, LeuB15, and ProB28; Fig. 3G).
To quantify the effects of relaxing the protein environment
on the B26 energy maps, corresponding (1,2) scans were
FIGURE 3. Rigid-body modeling of 3- and 5-[iodo-TyrB26]insulin analogs.
A, naive model of 3-[iodo-TyrB26]insulin highlights overlap of the iodine with
the side chains of IleA2 andValA3. B, analogousmodel of 5-[iodo-TyrB26]insulin
exhibits clash with TyrB16 and the backbone oxygen atom of GlyB20. This
view is slightly tilted relative to that in A to better illustrate the unfavorable
contacts. C, conformational rotational maps for a PC representation of the
B26 side chain around dihedral angles 1 and 2 for WT (left), 3-I-Tyr
B26 (mid-
dle), and 5-I-TyrB26 (right). The two energy scales highlight large (0–1000 kcal/
mol) and finer energy differences (0–50 kcal/mol) relative to the global min-
imum. The zero of energy for WT and 3-I-TyrB26 is at 0 kcal/mol, whereas the
minimum for 5-I-TyrB26 is relative to that of 3-I-TyrB26. The stars indicate oneof
the (1,2) conformations leading to severe steric clashes with neighboring
residues. The geometries are at 157°, 84°, 176°, 83°, and 151°, 84° for WT,
3-I, and5-I, respectively, and the clashing residues are listed.D is as inCbut for
a relaxed scanover the (1,2) grid. Thepanels showonly energies covering1
and2 intervals common to the threedimers as follows: [149°, 180°] for1 and
[53°, 85°] for 2. E and F contain respective rigid and relaxed conformational
rotational maps for an MTP representation of the B26 side chain. G, corre-
sponding structures in the neighborhoods of residue B26 (transparent red)
highlighting residues affected by dihedral rotations of B26 (orange): left to
right, WT insulin, 3-[iodo-TyrB26]insulin model, and 5-[iodo-TyrB26]insulin
model.
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obtained inwhich the positions of surrounding side chainswere
energy-minimized (Fig. 3D). As in the unrelaxed calculations,
the relaxed 5-I-TyrB26 energy map was similar to that of the
unmodified residue. Although the severe clashes found for 3-I-
TyrB26 were largely mitigated due to local adjustments, the
relaxed PC-based maps predicted that in an insulin dimer the
outward positioning of the iodine atom (5-I-TyrB26) would be
preferred by 1.3 kcal/mol relative to the 3-I-TyrB26 isomer.
Relaxation of neighboring side chains in the PC model thus
reversed the predicted orientation of the iodinated ring from in
to out. The 5-I basin also remained wider than that of 3-I.
Although the PC-predicted outward conformation of the
iodine atom seemed intuitive given the narrow confines of the
hydrophobic core and inferred flexibility of the dimer interface
(56–59), we next sought to test whether this prediction
remained valid using a more rigorous representation of the
halogenated side chain.
Representation of Residue B26 by anMTPModel—Given the
limitations of a PC-based force field, we employed an MTP
representation of iodo-Tyr parameterized as follows. The elec-
trostatic potential of ortho-iodophenol was mapped as a model
compound (Fig. 2B). The electron-donating property of the
para-hydroxyl group in iodophenol led to a partial attenuation
of iodine’s-hole togetherwith an increase in its negative equa-
torial potential region (	; Fig. 2B) relative to phenol. The elec-
tron-attracting property of the iodine induces non-local
decrease of the planar 	 -system above and below the plane
of the ring.
The unrelaxed MTP energy maps (Fig. 3E) validated aspects
of the PC calculations (Fig. 3C). The WT and 5-I maps were
similar to one another, and the 3-Iminimumwas again found to
be more favorable than that of 5-I-TyrB26 but with a narrower
basin. In striking contrast to the PC-based calculations, how-
ever, the relaxed MTP energy map (Fig. 3F) predicted the 3-I
minimum remained lower than that of 5-I, in this case by 5
kcal/mol. Hence, the more accurate electrostatic model (MTP)
led to a preferred position of the iodine in seeming contradic-
tion to our initial intuition.
B26 Interaction Energy Analysis—To understand the physi-
cal origins of theMTP prediction, interaction energies between
B26 and the neighboring dimer-related residues were analyzed
for the most energetically favorable 3-[iodo-TyrB26]insulin and
5-[iodo-TyrB26]insulin dimer structures. Both PC and MTP
electrostatic models were employed (supplemental Table S1).
The results suggested that, relative to the 5-I orientation, the 3-I
conformation provides both (i) favorable hydrophobic inter-
actions with the side chains of IleA2, ValA3, LeuB11, ValB12,
LeuB15, and ProB28; and (ii) favorable aromatic-aromatic
interactions distant from the halogen (PheB16 and PheB24).
Attractive, weakly polar interactions between 3-I-TyrB26 and
GlyB8 are also possible. In contrast, 5-I-TyrB26 engages in
favorable interactions only in the immediate neighborhood
of the iodine, and only with the ends of a solvent-exposed
and flexible -turn (GlyB20 and GlyB23). These key differ-
ences rationalize why an inward conformation is preferred
despite our initial expectation.
Multipole-basedMD Simulations Predicted Structural Features
of an Iodinated Insulin Analog
Side-chain conformations were further probed by analyzing
20 ns of four MTP-based MD simulations as follows: the WT
and 3-[iodo-TyrB26]insulin dimers, each in R2 or T2 states (sup-
plemental Figs. S1 and S2, respectively). Initial coordinates
were obtained from PDB entries 1DPH (T2) and 1ZNJ (as
extracted from a WT R6 zinc insulin hexamer). We first ana-
lyzed respective (1,2) occupancies, P(1,2), of residues
TyrA19, TyrB16, PheB24, PheB25, and TyrB26. Of these, A19
provided a probe of the -helical core within component
protomers, whereas B16 and B24–B26 provided probes of the
asymmetric dimer interface. The resulting dihedral angle dis-
tributions P(1,2) demonstrated that these side chains each
adopted conformations consistent with experiments (see sym-
bols in supplemental Figs. S1 and S2) with the exception of
PheB25 (whose variable conformation and asymmetry across the
dimer interface have previously been noted (2)). P(1,2) plots
were similar whether theMTP-basedMD simulations used T2 or
R2 starting structures, except for PheB25 (which agreed betterwith
crystal structures when starting from the R2 dimer).
3-I-TyrB26 Trajectories—Each subunit exhibited similar fea-
tures with optimal positioning of the iodine atom requiring a
change in B26 side-chain conformation (	1 
 10(3°) and
	2 
 5(8°); supplemental Figs. S1 and S2). Despite this
change, the aromatic face of 3-I-TyrB26 adjoined the side chain
of ValB12 as inWT insulin (supplemental Fig. S3A).MTP-based
MD simulations established that the 3-I-TyrB26 side chain
could pack within a hydrophobic cavity formed by the side
chains of IleA2, ValA3, LeuB11, andValB12 (and themain chain of
GlyB8) within the same protomer (supplemental Fig. S3B). The
predicted environment of 3-I-TyrB26 and its range of confor-
mational excursions were similar in R2- and T2-based MD
simulations.
The modified aromatic ring of 3-I-TyrB26 represents a per-
turbation within an anti-parallel dimer-related -sheet. The
subtle changes in the side-chain dihedral angles of 3-I-TyrB26
and 3-I-TyrB26 observed in the crystal structure of 3-[iodo-
TyrB26,NleB29]insulin (see below; relative to TyrB26 and TyrB26
in WT R6 hexamers) do not affect this sheet; its four dimer-
related hydrogen bonds exhibit essentially native lengths and
angles. Packing at the dimerization interface for theWT dimer
(supplemental Fig. S4A) and comparison with the predicted
3-[iodo-TyrB26]insulin dimer show that the iodine within each
protomeric corewithin theR6hexamerwould (a) provide anover-
all nonpolar environment and (b) enable formation of a novel
and favorable electrostatic interaction (supplemental Fig. S4B)
between the para-OHofTyrA19 and the equatorial belt surround-
ing the halogen (Fig. 2B). No halogen bonds were observed to the
-hole of the iodine (supplemental Fig. S4B).
5-I-TyrB26 Trajectories—MTP simulations of the alternative
5-I-TyrB26 ring conformation suggested that it could achieve
more compact packing at the dimer interface than was observed
for WT or 3-I-TyrB26 simulations (supplemental Fig. S3C).
The simulations further verified the implications of the MTP
energy maps that unfavorable steric and electrostatic interac-
tions across the dimer interface render unfavorable 5-I-posi-
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tioning of the iodine atom. The clash between the 5-iodine and
the dimer-related side chain of TyrB16 could not be relieved by
displacement of B16 because it itself is constrained by ValB12
and PheB25 (supplemental Fig. S3C). Although a clash between
the 5-iodine and the dimer-related carbonyl oxygen of GlyB20
could readily be relieved by a change in B20 main-chain dihe-
dral angles (supplemental Fig. S5), the resulting B20 conforma-
tions (with negative 
 angles in the Ramachandran plane) are
less favorable (60). Previous studies of synthetic insulin analogs
have shown that reinforcement of the native positive
 angle by
D-AlaB23 stabilizes insulin, whereas perturbation of the B23
conformation by L-Ala or L-Val (the latter associated with
human diabetes) is associated with structural frustration and
misfolding (60, 61).
The robustness of the MTP-MD simulations was probed
through average r.m.s.d. on pairwise comparisons of the con-
formations sampled in the course of 20-ns trajectories. The
values given in Table 1 pertain to side chains at the dimer inter-
face (residues B24, B25, and B26) following alignment based on
the main-chain atoms of residues B24–B28 and B24–B28.
Baseline r.m.s.d. values in the WT T2 dimer (PDB code 1DPH)
were calculated following a control MD simulation (i.e. in the
absence of amodified B26). For residues in theWTanti-parallel
-sheet (residues B24–B28 and their dimer-related mates), the
average main-chain r.m.s.d. was 0.1 Å, and the average side-
chain r.m.s.d. was 0.3 Å relative to starting structure (Table 1).
Corresponding values for the modified T2 dimer were 0.3 and
0.9 Å, also relative to the WT crystal structure; similar values
were obtained on comparison of the modified R2 dimer. The
larger r.m.s.d. values in the modified dimers reflected consis-
tent conformational adjustments required to accommodate
core packing of the iodine atom in the 3-I conformation.
Crystal Structure Verifies Essential Features of MTPModeling
3-[iodo-TyrB26,NleB29]Insulin exhibited an affinity (Kd) for
the lectin-purified receptor (isoform IR-B) of 21 5 pM under
conditions in which WT insulin exhibits an affinity of 62(8)
pM. The analog’s stability (	Gu 
 3.4(0.1) kcal/mol at 4 °C)
was indistinguishable from that of [NleB29]insulin as probed by
guanidine denaturation (32).
The analog was crystallized under conditions that ordinarily
facilitate crystallization ofWT insulin as a phenol-stabilized R6
hexamer (23). A monoclinic lattice was observed in which one
R6 hexamer defined the asymmetric unit (for refinement statis-
tics, see Table 2). In this crystal form, each protomer in the
hexamer is crystallographically independent (and so may in
principle exhibit subtle structural differences). A ribbon model
(Fig. 4A) highlights the positions of the iodine atoms (green
spheres) relative to the six R state-specific B1-B19 -helices
(green) andA chains (black).We first describe the structure and
then compare it to the predicted models.
Crystal Structure of 3-[iodo-TyrB26,NleB29]Insulin Resembles
theWTHormone
No significant differences were observed between the modi-
fied hexamer and the corresponding WT R6 hexamer with
respect to secondary structure, chain orientation, mode of
assembly, or structures of the Zn2- and phenol-binding sites.
The six independent R state protomers exhibited essentially
identical conformations (average pairwise main-chain r.m.s.d.
of 0.42 Å and average side-chain r.m.s.d. of 1.43 Å). Tetrahedral
coordination of the two axial zinc ions (overlying red spheres at
center in Fig. 4A) by the side chains of HisB10 (three per R3
trimer; light gray side chains) is essentially identical to that in
WT R6 hexamers (62); the fourth coordination sites contain a
presumed chloride anion. In each protomer, the B26 iodine
atom is positioned within the -helical core in accordance with
the 3-I-conformational isomer. No excess electron density was
observed at ring position 5, providing evidence of a single pre-
dominant conformation.
Superposition of a representative analog protomer and WT
protomer (dark and light gray ribbons, respectively, in Fig. 4B)
yielded the following average pairwise differences between a
representative protomer of 3-[iodo-TyrB26,NleB29]Insulin and
theWT R state: main-chain r.m.s.d.
 0.55(0.08) Å and side-
chain r.m.s.d. 
 1.94(0.23) Å. These values are similar to
those observed among a collection of independent WT R state
protomers13 (main-chain r.m.s.d. 0.68(0.26) Å; side-chain
r.m.s.d. 1.14(0.34) Å).Within the crystal structure of 3-[iodo-
13 WT R state coordinates were obtained from PDB entries 1TRZ, 1TYL, 1TYM,
1RWE, 1DPH, and 1ZNJ.
TABLE 1
Average r.m.s.d. across dimer interface
Average r.m.s.d. across theWT-T2, 3I-TyrB26 T2, and R2 dimer interface from 20 ns
of MD simulation and from the three dimers (D1, D2, and D3) taken from the
3-I-TyrB26 R6 crystal structure, with respect toWT (PDB code 1DPH). All structures
are aligned with respect to the backbone atoms of residues B24–B28 and B24–
B28. Values reported are r.m.s.d. of the side chains of residues B24–B26 and
B24–B26.
Comparison r.m.s.d. (Å)
WT1DPH/WT (20 ns MD) 0.3
WT1DPH/T2 3-I-TyrB26 (20 ns MD) 0.9
WT1DPH/R2 3-I-TyrB26 (20 ns MD) 1.0
WT1DPH/D1 of R6 3-I-TyrB26 X-ray 0.7
WT1DPH/D2 of R6 3-I-TyrB26 X-ray 0.7
WT1DPH/D3 of R63-I-TyrB26 X-ray 0.7
TABLE 2
X-ray data processing and refinement statistics
Wavelength (Å) 1.5478
Resolution range (Å) 40.85–2.30 (2.40–2.30)a
Space group P21
a (Å), b (Å), c (Å),  (°) 46.43, 61.63, 58.58, 111.38
Redundancy 4.76 (2.55)
Completeness (%) 95.6 (80.4)
Rmerge 0.054 (0.227)
I/(I) 18.2 (3.9)
CC1/2b 0.999 (0.934)
Refinement
Resolution range (Å) 40.85–2.30
No. of reflections 13,255
Rwork/Rfreec 0.163/0.228
No. of protein atoms 2305
No. of non-protein atoms 121
Biso protein atoms (Å2) 41.6
Biso non-protein atoms (Å2) 34.0
bonds (Å)/angles (°) 0.008/1.12
Ramachandran plot
Favored (%) 100
Outliers (%) 0
aNumbers in parentheses refer to the outer resolution shell.
b Pearson correlation coefficient between merged intensities of two random halves
of the diffraction data set (112).
c Free set contained 10% of total observed reflections.
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TyrB26,NleB29]Insulin, no polypeptide-like (2Fobs Fcalc) elec-
tron density (continuous at 1) was observed C-terminal to
B28 in any of the modified B chains.
The similarity of the variant andWT structures suggests that
the essential features required for dimer formation are not
altered by the asymmetric distribution of partial charges in the
aromatic ring of 3-I-TyrB26 and its associated pattern of aro-
matic-aromatic interactions (supplemental Fig. S4C). The six
independent side chains of 3-I-TyrB26 nonetheless exhibit
consistent differences in conformation relative to WT TyrB26
(supplemental Fig. S4D). The modified side chain (dark gray in
supplemental Fig. S4D) is rotated by 12° about the C–C
bond with respect to its WT counterpart (light gray in supple-
mental Fig. S4D). As predicted by theMTP-based calculations,
this rotation positions the iodo-group within a non-polar
pocket formed by the side chains of residues IleA2, ValA3,
LeuB11, and ValB12, residues conserved among vertebrate insu-
lins and essential for biological activity (2). In theWT structure,
the pocket is occupied by the phenolic hydroxyl group of
TyrB26, although its packing within the pocket is less intimate
than that of the iodine atom of 3-I-TyrB26. The consequent
displacement of the para-hydroxyl group of 3-I-TyrB26 from
the pocket results in its greater solvent exposure. Side-chain
dihedral angles of three aromatic side chains at or near the
dimer interface (B16, B24, and B26) are given in Table 3 in
relation to a reference WT R6 structure.
As expected, the 3-[iodo-TyrB26,NleB29]Insulin hexamer
contains six bound phenol molecules, located at an interface
between dimers as in the WT R6 hexamer (23). The phenol-
binding sites are essentially identical. The electron density
(2Fobs  Fcalc) associated with one such phenol is shown in
relation to a superposition of variant and WT structures (dark
and light gray in Fig. 5, A and B). In each case, a characteristic
pair of hydrogen bonds from the phenolic –OH group engages
the main-chain carbonyl oxygen (acceptor) and amide group
(donor) of CysA6 and CysA11, respectively. A corresponding
depiction of B26 side chain environments highlights the asymme-
try in density between the 3- and 5-ring positions (Fig. 5,C andD).
Accommodation of the modified side chain does not alter the
canonical hydrogen-bonding pattern of the dimer-related anti-
parallel -strands (B24–B26 and B26–B24 segments) (Fig. 6A).
Although differences in side-chain conformation (relative toWT)
were observed at B25, its side-chain density was poor, suggesting
dynamic disorder (Fig. 6B). We speculate that these differences
reflect slight alterations in backbone geometry; variation in the
crystallizationmilieu cannot be excluded.
Comparison of Observed and Predicted Conformations of
3-I-TyrB26
The average r.m.s.d. across the dimer interface was calcu-
lated for the three 3-I-TyrB26 insulin R2 dimers with respect to
WT R2 dimers (PDB code 1ZNJ; Table 1). The deviation in the
3-I-TyrB26 R2 dimers (0.7 and 0.9 Å) arises from the packing of
iodine in the hydrophobic pocket. The average r.m.s.d. across
the dimer interface was also calculated with respect to the crys-
FIGURE 4. Crystal structure of 3-[iodo-TyrB26,NleB29]Insulin. A, R6 hexamer with A and B chains (black and green ribbons, respectively). Iodine atoms (green
spheres) and the two axial zinc ions (red spheres) are aligned at center, each coordinated by 3-fold-related HisB10 side chains (light gray). B, superposition of WT
protomer (light gray) and 3-I-TyrB26 analog (dark gray). Side chains of TyrB26 and 3-I-TyrB26 are shown as sticks. For clarity, the iodine atom is shown as a
transparent sphere; NleB29 is not shown.
TABLE 3
Side-chain dihedral angles of aromatic side chains near dimer
interface
PheB25 has been excluded due to poor side-chain density found in the crystal
structure.
Residue
3-I-TyrB26 WT insulina
1 (°) 2 (°) 1 (°) 2 (°)
TyrB16 172.4 78.8 174.7 77.6
176.9 83.1 179.6 80.8
175.4 82.9 172.9 84.3
174.5 81.1 177.6 84.6
177.0 79.2 175.9 75.5
178.0 79.6 175.3 66.2
PheB24 63.2 87.6 62.5 89.1
69.9 88.4 69.3 83.2
60.0 85.3 59.3 83.4
63.0 86.9 55.2 85.0
60.1 89.0 56.7 87.9
61.0 87.5 68.8 87.5
TyrB26 167.8 74.1 173.9 82.7
166.6 81.0 168.9 90.5
161.4 72.6 176.7 69.8
167.7 75.3 176.5 74.7
168.1 75.7 173.9 80.1
165.3 78.0 175.4 72.4
aMolecular coordinates were obtained from PDB code 1ZNJ.
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tal structure of theWTT2 dimer (PDB code 1DPH). Because in
the T state GlyB8 lies within a -turn (with positive 
 angle)
whereas the R state has B8 in an -helix (negative  angle), the
T2-related r.m.s.d. was calculated only for backbone atoms of
the -sheets at the dimer interface (/).
The 1 and 2 dihedral angles of selected side chains in the
three dimers in the crystallographic hexamer were compared
with the predicted dimer dihedral angle distribution fromWT-
and 3-[iodo-TyrB26]insulin T2 dimers (black stars for dimer 1,
black squares for dimer 2, and black circles for dimer 3; see
supplemental Fig. S2). In the crystallographic hexamer, the aro-
matic residues locally re-organize such that B24 and B24
always have opposite 2 angles (this is observed for all the
dimers in the crystal); in contrast, the B25 side chains are dis-
ordered. Simulations, 20 ns in length, based on the R2 structure
(PDB code 1ZNJ) established that the R2 dimer samples all
experimentally observed states. As a control to test whether
such consistency would be affected by the TR transition, corre-
sponding trajectories based on a crystallographic T2 dimer
(PDB code 1DPH) were undertaken (supplemental Fig. S2).
Although sampling of B25 side-chain conformations (and to
some extent that of PheB24) differed in the T2 trajectory (sup-
plemental Fig. S2), the results were in good overall agreement
with the R2-based simulations (supplemental Fig. S1).
Molecular Modeling of 3-[iodo-TyrB26]Insulin at theIR
Interface
Howmight iodo-TyrB26 enhance the binding of insulin to the
receptor? The environment (and conformation) of iodo-TyrB26
in the variant hormone-IR complex is likely to differ from its
internal environment in the modified zinc hexamer, given that
in the co-crystal structure of theWTIR complex the B23–B27
segment is displaced from its location in the free hormone (Fig.
1C) (39). Such displacement permits the aromatic rings of
PheB24, PheB25, and TyrB26 to contact the receptor (Fig. 7). The
open receptor-bound conformation of the hormone is thus pre-
dicted to expose the side chain of 3-I-TyrB26 and in particular
enable its engagement at the L1-CT surface.
We hypothesized that the enhanced affinity of this and
related iodo-TyrB26 analogs (7, 63, 64) might be due to a novel
interaction between the halogen atom and the IR. MD simula-
tion of 3-I-TyrB26 and 5-I-TyrB26 at the IR interface (using
PDB code 4OGA as starting structure) supported the plausibil-
ity of thismodel (Fig. 7). An iodine at either the 3- or 5-positions
(Fig. 7) of TyrB26 could readily be accommodated within the
receptor-binding cleft (i.e. with the iodo group directed either
toward or away from the IR interface). Whereas the 5-I-
TyrB26 conformation did not appear to offer new favorable
interactions, our modeling revealed that a 3-iodo-substituent
could participate in three novel contacts (Fig. 8A) as follows: (i)
a halogen bond between its 	 region and the backbone oxygen
atom of Val-712, and (ii and iii) favorable electrostatic interac-
tions between its 	 equatorial belt (Fig. 2B) and one hydrogen
from the -NH2 of Gln-34 and one hydrogen from the -NH2 of
Arg-14. Details are as follows.
The predicted halogen bond at the variantIR interface rep-
resents a “gain of function” by a nonstandard side chain (65). In
FIGURE 5. Crystallographic features of R6 3-[iodo-Tyr
B26]insulin hexamer. A, (2Fobs Fcalc) difference A-weighted electron density contoured at the 1
level of a representative bound phenolmolecule. Its para-OH group participates in hydrogen bondingwith the carbonyl oxygen of CysA6 and amide proton of
CysA11 (cystine A6–A11). An edge-to-face interaction occurswith the imidazole ring of HisB5 from another dimer. B, stereo view as inA aligning the structure of
the analog (dark gray) with that ofWT insulin as an R6 hexamer (light gray). C, electron density of 3-I-Tyr
B26 and surrounding residues.D, stereo view of residues
seen in C (stick representation) superposed as in B. WT coordinates for B and Dwere obtained from PDB code 1ZNJ.
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the predicted halogen bond, the average distance between the
iodine and the carbonyl oxygen of Val-712 is 3.6 Å, which is less
than the sum of their van derWaals radii (4.1 Å) (Fig. 8B, upper
panel). However, the estimated -hole size of iodine bound to a
phenol, and so ortho to its hydroxyl group, is smaller due to the
latter’s electron-donating properties (see Fig. 2B). The -hole
size is represented by angle  (Fig. 2C), typically 148° for iodine
bound to phenyl; the directionality of the halogen bond is along
the C–I bond axis (55). For 2-iodophenol, this angle is smaller
(106°), and the halogen-bond direction shifted from the C–I
bond by30° (Fig. 2C). Thus, the -hole bond angle  is within
the 	 region that ranges from 127° C-IO to 233° (Fig. 2C).
The-hole bond angle distribution C-IO, of the iodine atom (I)
with the backbone O of Val-162 from 1-ns MD, ranges from
127 to 170° and peaks at 145°, whereas the C-IH distributions
are within the 	 region (Fig. 8C). The IO distance of 3.6 Å
and the C-IO angle of145° favor formation of a strong hal-
ogen bond in the complex as suggested by previous quantum-
chemical calculations (66) andMDstudies of other systems (55,
67, 68).
In essence, our modeling suggested that 3-I-TyrB26 leads to
an increased number of local interactions at the IR interface
with retention of native contacts. All-atom simulations thus
rationalized the increased affinity of such insulin analogs for the
intact receptor. As a further control to test whether such
increased affinity is electrostatic or nonpolar (van derWaals) in
nature, we undertook additional simulationswith an atom-cen-
teredPC force field andwith a simplified force field inwhich the
iodine only engaged in van der Waals interactions. In contrast
to theMTP electrostatic model (upper panel in Fig. 8B), the PC
model exhibited only one of the above three contacts: that to
Gln-34 (lower panel).Moreover, a “neutral” iodine (q
 0) led to
detachment of TyrB26 from the IR surface after 150 ps (Fig.
9A). These control simulations suggest that the increased
receptor-binding affinity of 3-[iodo-TyrB26]insulin is driven by
electrostatics at the level of quantum chemistry rather than a
consequence of the hydrophobicity of iodine (Fig. 9B). The
potential role of water molecules at the modified interface is
discussed below.
Discussion
This study has focused on position B26, broadly conserved as
Tyr among vertebrate insulins and as Phe among insulin-like
growth factors (69). Although non-polar and charged side
chains at B26 are compatible with high affinity for the IR, such
insulin analogs are unstable and prone to fibrillation (32).
Of the natural amino acids at B26, Tyr thus appears to offer
the best combination of activity and stability. How might the
expanded chemical space of unnatural mutagenesis (70) be
exploited to enhance the biophysical properties of an active
insulin molecule? We approached this question in three parts.
We first simulated the structure of [iodo-TyrB26]insulin (as a
dimer) to predict how the iodine atoms could be accommo-
dated. This simulation, critically dependent on the quantum-
chemical properties of an iodo-aromatic group, suggested that
the iodine might enhance (rather than perturb) native packing
interactions within the core of the free hormone. We next ver-
ified the predicted conformational preference for the 3-I-
TyrB26 state through crystallographic studies. Finally, we inves-
tigated possible mechanisms by which 3-I-TyrB26 enhances IR
binding (7–9). Such enhancement posed a seeming paradox as
a modification that “closes” the free conformation of insulin
FIGURE 6. Side-chain arrangements within dimer interfaces. Residues
B23–B26 are shown within respective crystal structures of the 3-[iodo-
TyrB26,NleB29]insulin hexamer (A) and WT insulin R6 zinc hexamer (PDB code
1ZNJ) (B). The three subpanels within A and B correspond to the respective
three copies of the dimer interface within the crystallographic asymmetric
units of the two structures. Within each subpanel, the side-chain carbon
atoms of PheB24 and its non-crystallographic symmetry equivalents are
shown in green, of PheB25 and its non-crystallographic symmetry equivalents
in orange, and of 3-I-TyrB26 or TyrB26 and their non-crystallographic symmetry
equivalents in light purple, whereas all backbone atoms are in yellow, as are
the side-chain atoms of ThrB27 and its non-crystallographic symmetry equiv-
alents. The arrows on the right assist in identifying the direction of the respec-
tive polypeptides within each subpanel. Chains within each subpanel corre-
spond (from left to right) to chains B, D, F, H, J, and L (respectively) within each
structure. Overlaid on the three subpanels in A is A-weighted (2Fobs Fcalc)
difference electron density contoured at the 0.75  level and masked to
within2.5Åof the side-chain atomsof PheB25 and its symmetry-relatedequiv-
alents. The valuesdisplayedunder the respective chainswithin the subpanels
ofB correspond to the side-chain occupancies of the PheB25 and its respective
non-crystallographic symmetry equivalents within PDB code 1ZNJ. The side
chain of NleB29 is not shown.
FIGURE 7. Homology model of IR/insulin interface. Docked structure of
3-[iodo-TyrB26]insulin bound to L1 (Arg-14 and Gln-34) and CT (Val-712) of
the IR. 5-[iodo-TyrB26]insulin has the iodine away from the interface
(through rotation around theC–C axis (2 180°); see Fig. 2A) and is expected
to interact less favorably with the IR.
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(45) might have been expected to impair its ability to open on
receptor binding (39, 71).
The structure and properties of 3-[iodo-TyrB26]insulin
reflect general physico-chemical principles. Packing of an iodo-
aromatic modification within the core of a globular protein in
principle reflects its overall hydrophobicity (72) and stereo-
electronic properties (18). Indeed, modification of one edge of
an aromatic system both introduces a unique local electronic
distribution (i.e. at the halogen) and alters the overall electron
density of the -electronic cloud, including at the opposite
edge. These features are exemplified by crystal structures of
thyroid hormone bound to its nuclear receptor (73) or carrier
proteins (74). Because thyroid hormonemay have evolved from
an ancestral iodo-Tyr (as in its route of biosynthesis (75)), we
may regard iodinated derivatives of insulin as models for iodo-
aromatic chemistries related to this evolutionary innovation.
FIGURE 8. MD-based model of IR/3-[iodo-TyrB26]insulin interface. A, structure of 3-[iodo-TyrB26]insulin bound to the IR. Only IR residues interacting
with 3-I-TyrB26 are illustrated. Potential hydrogen/halogen bondswith iodine are shown as dashed arrows. B, probability distribution along the C-IR distance,
where R is (O
C(Val-365)) (red line); R is (H-N(Gln-81)) (green line); or R is (N2(Arg-61)) (dashed orange line). The upper panel is from simulations with MTP
electrostatics, whereas the lower panel uses point charges. The black dashed lines at 4.1 Å (3.7 Å, lower panel) represents the C-IO(Val-365) interaction limit
using optimized van derWaals radii for the iodine and oxygen atoms.Dashed lines at 3.7 Å (3.3 Å, lower panel) indicate the C-IH (Gln-34 and Arg-14) distance
using optimized van derWaals radii for iodine and polar H-atoms. C,probability distribution of the halogen/hydrogen bond angular variation C-R from1 ns of
MD simulation. The black dashed line at 127° represents the boundary between the negative (	  127°) and positive electrostatic region (127° 	 233°)
for I.
FIGURE 9.MD-basedmodel ofIR/3-[iodo-TyrB26]insulin interface assuming neutral iodine. A, time evolution of the IR distance (distance of TyrB26-I to
the interacting insulin/IR residues). The upper and lower panels show the increase of the IO
C(Val-365), IH-N(Arg-61), and IH-N(Gln-81) bond lengths,
respectively, and the decrease of the IC(Lys
B29), IH-NE(His-79), IC(Pro
B28), and IO
C(ThrB27) bond lengths in the course of theMD simulation. The black
dashed line at 150 ps represents the point when the electrostatically driven interactions dissociate and the van der Waal-driven interactions form. B, snapshot
structure of 3-[iodo-TyrB26]insulin bound to the IR. Only the residues interacting with 3-I-TyrB26 are illustrated. Bond formation/dissociation with the iodine
atom are shown as full and dashed line arrows, respectively.
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The present structure and MD simulations highlight that aro-
matic-rich protein interfaces are not classical ball-and-stick
objects.
Modification of Residue B26 Enhances Packing Efficiency
3-I-TyrB26 represents an apparent perturbation within an
anti-parallel dimer-related -sheet. The subtle changes in the
side-chain dihedral angles of 3-I-TyrB26 and 3-I-TyrB26
observed in the crystal structure of 3-[iodo-TyrB26,NleB29]
Insulin (relative to TyrB26 and TyrB26 in WT R6 hexamers) do
not affect this sheet; its four dimer-related hydrogen bonds
exhibit essentially native lengths and angles. Side-chain packing
schemes in the WT insulin dimer within the R6 hexamer (Fig.
4A) and its comparison with the 3-[iodo-TyrB26]insulin dimer
demonstrate that the iodine atoms both (a) reside within an
overall nonpolar environment within each protomeric core,
and (b) enable formation of a novel and favorable electrostatic
interaction (supplemental Fig. S4B), i.e. between the para-OH
of TyrA19 and the equatorial belt surrounding the halogen (Fig.
2B). The latter contact is analogous toweakly polar interactions
between hydrogen-bond donors (such as the carboxamideNH2
of Asn orGln) and the planar cloud of aromatic rings (44). No
halogen bonds were observed (supplemental Fig. S4, B and D).
Despite the larger size of iodine relative to hydrogen, only a
slight re-arrangement occurs within the modified hormone
core. Indeed, the internal location of the iodine atom in the
crystal structure of 3-[iodo-TyrB26,NleB29]Insulin highlights a
potential packing “defect” inWT insulin. Such gaps are in gen-
eral widespread among crystal structures of globular proteins,
as reflected bymean side-chain packing efficiencies of 70–80%
(76). Perfect packing efficiency is not attainable given the dis-
tinct sizes, shapes, and preferred dihedral angles of amino acids.
The existence and ubiquity of such cavities was highlighted in
seminal studies of xenon-saturated cores (77). The packing of
3-I-TyrB26 near the side chains of A2, A3, and A19 in the pres-
ent structure is thus reminiscent of the accommodation of large
xenon atoms within the core of myoglobin (77).
3-I-TyrB26 Modulates Aromatic-Aromatic Interactions
The dimer interface of insulin exhibits successive aromatic-
aromatic interactions involving eight residues: TyrB16, PheB24,
PheB25, TyrB26, and their dimer-related mates (2). Whereas the
two B25 side chains lie at the periphery of this interface (and
exhibit alternative or multiple conformations amongWT crys-
tal structures (2)), the remaining six aromatic rings conform to
favorable pairwise edge-to-face orientations (44). Respective
aromatic-aromatic interactions at the dimer interface of WT
insulin and 3-[iodo-TyrB26,NleB29]Insulin are shown in Fig.
10B. Inter-ring centroid distances and orientations are
defined as illustrated in Fig. 10A (44). In a representativeWT
R6 structure (determined at a resolution of 2.0 Å with one
hexamer in the asymmetric unit such that the three dimer
interfaces are crystallographically independent; PDB code
1ZNJ), the dimer interface contains the following structural
relationships.
Dimer-related Neighbors—The nearest pairs of rings in the
WTR6 hexamer are across the dimer interface as follows: B16–
B26 and B26–B16 (5.8/5.7, 5.8/5.5, and 5.7/5.5 Å in respective
interfaces BD, FH, and JL as defined in the PDB); B24–B24
(5.8, 5.7, and 5.9 Å), B24–B26 and B26–B24 (6.2/6.2, 5.9/5.8,
and 5.8/6.1 Å). Detailed differences pertaining to B16–B26/
B16–B26 and to B24–B26/B24–B26 distances reflect subtle
asymmetries at each interface. Structural relationships
between B16–B26 and between B16–B26 closely conform,
in each of these six pairs, to the canonical edge-to-face pack-
ing of benzene rings (44) with mean polar angles  

136(4) and 
 
 49(4)° and mean inter-plane dihedral
angle 
 136(4)° using polar coordinates as defined in Fig.
10A. The three B24–B24 pairs exhibit displaced edge-to-
face packing.
Intra-chain Relationships—Within each WT B chain, the
side chains of PheB24 and TyrB26 project from the same side of a
-strand but (due to their respective 1 and 2 dihedral angles)
exhibit edge-to-face interactions rather than  stacking (Fig.
10B). Theirmean centroid distance is (r) 7.5(0.1) Åwith aver-
age  values of 116(2) and 

 54(3)° and with inter-plane
dihedral angle 62(8)°. Corresponding intra-chain centroid
distances between TyrB16 and TyrB26 are more distant (r 
 13.4
(0.1) Å), beyond the range of a favorable weakly polar inter-
action (44).
FIGURE 10. Aromatic-aromatic interactions. A, axes and definition of polar
coordinates (r, 
, and ) as originally defined by Burley and Petsko (44). 
provides the dihedral angle between the two planes formed by each of the
aromatic rings. The two interacting aromatic rings are shown in red. B, inter-
acting pairs of aromatic rings at the dimer interface of WT insulin and the
3-I-TyrB26 analog. Upper panel, PheB24/TyrB26, PheB24/PheB24, PheB24/TyrB26,
and TyrB26/TyrB16; primed residue numbers indicate the dimer-related resi-
due A representative WT structure (green) is overlaid in comparison with the
side chains of the 3-[iodo-TyrB26,NleB29]insulin structure (cyan). Lower panel,
PheB25/PheB25 interaction pair and its three possible conformations. Images
of representative PheB25 side chains from the crystal structure of 3-I-TyrB26;
the side chains of [NleB29]insulin are not shown due to dynamic disorder. WT
coordinates were obtained from PDB code 1ZNJ.
Halogen-based Protein Engineering
27034 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 53•DECEMBER 30, 2016
 at U
niversitaetsbibliothek M
edizin on January 25, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Alternative Occupancies of PheB25—Although the side chains
of PheB25 in theWT crystal form can adopt two conformations,
onemode corresponds to displaced stacking (B25–B25) with
a centroid distance of 5.6 Å. This mode represents a distinct
motif of aromatic-aromatic interaction from a quantum-
chemical perspective (44). It is also possible for the two B25/
B25 aromatic rings to each point inward (i.e. toward TyrA19
in its own protomer), attenuating their aromatic-aromatic
interaction.
The crystal structure of 3-[iodo-TyrB26,NleB29]Insulin exhib-
its only subtle differences relative to the above. The altered 1
and 2 dihedral angles of 3-I-TyrB26 and 3-I-TyrB26 (1 
 166
(2.5) and 2
 76(3)°) enable packing of the iodine atom in
a gap bounded by conserved side chains in both chains (IleA2,
ValA3, TyrA19, LeuB11, ValB12, LeuB7, and cystine A7–B7; see
supplemental Fig. S4D). Respective side-chain conformations
of residues B26 and B26 across each of the three (crystallo-
graphically independent) dimer interfaces are similar but not
identical (Table 3). Repositioning of the B26/B26 side chains is
in turn associated with subtle changes in geometric parameters
describing B26–B16 (and likewise B26–B16), B26–B24 (also
B26–B24), and B26–B24 (Fig. 10B and Table 3). Of these, the
most distinct pairwise orientations (relative to the WT refer-
ence structure) are exhibited by B26–B16 and B24–B26.
These in turn necessitate a small change in the relative B24–
B24 positions.
Of future interest would be comparison of iodo-TyrB26 with
iodo-PheB26 as a test of the predicted effect of the former’s
para-OHgroup on the position and intensity of iodine’s-hole.
Comparison of such modifications with smaller halo-aromatic
substitutions would likewise enable local effects of the halo-
gen’s electronic distribution to be distinguished from general
long range effects on the overall dipolemoment of themodified
aromatic system.
Application ofMTPModeling to the Variant Hormone-
Receptor Complex
Our efforts to apply MM methods to the modified insulin
dimer highlighted the importance of accurate representations
of the iodo-aromatic ring and its interactions. Indeed, a PC-
basedmodel of the iodo-Tyr predicted (incorrectly) an outward
orientation of the iodine atom (5-I-TyrB26), whereas an MTP-
based model favored the observed inward orientation (3-I-
TyrB26). These findings are in accordance with previous simu-
lations of small molecules wherein halogenated compounds
required an MTP treatment, although electronically less
demanding building blocks (such as N-methylacetamide) did
not (67, 78). Experimental verification of MTP-based predic-
tions in the case of the insulin hexamer encouraged us to sim-
ulate the possible function of iodo-TyrB26 at the surface of the
IR complex (39, 71).
In the WT insulin-IR complex, invariant L1 residues
Arg-14 and Gln-34 are of special interest (39, 71). The side
chain of Arg-14 contacts the main chain of PheB25 and defines
one edge of the crevice (together with Asp-12) in which the
main chain and side chain of TyrB26 loosely pack. The side-
chain carboxamide of Gln-34 forms a hydrogen bond with the
carboxylate of Asp-12, which in turn forms bidentate charge-
stabilized hydrogen bonds to an -NH2 and 	-NH of Arg-14
below an aromatic ring of TyrB26 (Fig. 11A). This canonical
Asp-Argmotif appears to be critical asAla substitution of either
residue markedly impairs the binding of insulin (71, 79, 80). In
the predicted structure of the 3-[iodo-TyrB26]insulin/IR
interface, these native-like contacts are retained and extended
by favorable electrostatic interactions with the equatorial belt
of the halogen (Fig. 11B). In particular, one hydrogen in the key
Arg14-NH2 group hydrogen-bonds with Asp-12, whereas the
other hydrogen engages the 	-equatorial zone of the iodine.
Both hydrogens of the second -NH2 group of Arg-14 interact
with the carbonyl oxygen of Val-713 in CT; this bifurcated
pair of hydrogen bonds has lengths of 1.8 and 2.3 Å with an
acute angle (60°) between the two hydrogen bonds. Our
model thus integrates the asymmetric electronic distribution
around the iodine atom within a pre-existing charge-stabilized
hydrogen-bond network inferred to exist in the WT complex.
The conformationally averaged IHdistances to the respective
side chains of Gln-34 and Arg-14 are 2.9 and 3.2 Å.
WaterMolecules Are Integral to the Predicted Hormone-
Receptor Interface
In theWT-IR complex Val-712 lies at the C terminus of the
CT -helix, and its carbonyl oxygen participates only in a
weak-capping (i,i 3) hydrogen bond to themain-chain NH of
non-helical residue Val-715 (distance 3.6 Å and angle 113°; Fig.
11A). In the predicted structure of the [iodo-TyrB26]insulin
complex, the carbonyl oxygen of Val-712 forms bifurcating
interactions, the native hydrogen bond to Val-715, and the
novel halogen bond to the -hole of the iodine. The angle
between the hydrogen bond and halogen bond is 75°. This
interface is thus remarkable for the large number of stabilizing
electrostatic interactions (Fig. 11B). Although the IR co-crys-
tal structure was of insufficient resolution to define the bound
structure in detail, the B26-related crevice is exposed to solvent,
and our MD simulations predicted formation of a bound water
network anchored by the para-OH of TyrB26 and the carbonyl
oxygens of Asn-711, Val-712, and Phe-714 (Fig. 11C). In the
[iodo-TyrB26]insulin complex, this network is retained and
reinforced by interactions between the iodine and hydrogen
atoms of three water molecules (Fig. 11D); one of these water
molecules bridges the neighboring iodine and para-OH of the
modified TyrB26 (Wat3 in Fig. 11, E and F).
Together, the 	-equatorial zone of the iodine atom is thus
predicted to engage five hydrogen atoms, three fromwatermol-
ecules and two from L1 side chains Arg-14 and Gln-34
(as above; Fig. 11, E and F). Given the atomic radius of iodine
(2.4 Å), its circumferencemay be estimated as30Å, sufficient
to accommodate these five contacts. One of the above three
water molecules (Wat1) also contacts the water molecule
(Wat2) anchored by the carbonyl oxygen of Val-712 (Fig. 11F)
and in turn a hydrogen-bonded network involving Val-712
(C
O)H(W2)O(W1)I(TyrB26). A striking prediction of
this model is thus that a water-CT network bridges the 	-e-
quatorial zone of the iodine atom with its 	 -hole.
Might the predicted iodine-anchored network of interfacial
water molecules be observable in future co-crystal structures?
To address this issue, we computed thermal B-factors from the
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fluctuation around average positions. We first focused on the
three putative water molecules (Wat1, Wat2, and Wat3)
involved in hydrogen bonds with (or bridging between) the
iodine atom, the para-OH of TyrB26, and the carbonyl oxygen
of Val-712. Each of these H2O oxygen atoms was predicted to
exhibit a B-factor40 Å2, significantly lower than that of other
water molecules at this interface (100 Å2) and similar to the
B-factors of the C atoms of Val-712, Arg-14, and Gln-34 (i.e.
30 Å2). Moreover, the number of water molecules within 4 Å
of the iodine atom at the 3-I-TyrB26/IR/water interface rang-
ing from 1 to 5 with an average of 3 during 1 ns of equilibrium
MD simulation (supplemental Fig. S6). A similar analysis of the
WT insulin/IR/water interface also found strongly interacting
water molecules, albeit with increased B-factors (50 Å2). We
therefore anticipate that the three predicted iodine-anchored
structural water molecules should be observable by crystallog-
raphy in a sufficiently well ordered crystal.
Concluding Remarks
The promise of non-standard insulin analogs to enhance the
treatment of diabetes mellitus represents an important frontier
of molecular pharmacology (81). Indeed, substitution of TyrB26
by 3-I-Tyr in the rapid-acting analog insulin lispro enhances its
stability and resistance to fibrillation while maintaining its bio-
logical activity (45). The present crystal structure has demon-
strated how the modified side chain pivots to enable burial of
the iodine atom in the hydrophobic core.Despite such apparent
optimization of the free state (45), 3-I-TyrB26 also enhances
FIGURE11.Predictedwaternetworkat theIR/insulin interface.AandB, local interactionat the interface aroundTyrB26 inWT insulin (AandC) and3-I-TyrB26
insulin (B andD–F). The interactions involve Asp-12, Arg-14, and Gln-34 of L1; Val-712, Val-713, and Val-715 ofCT; andwith PheB25 and TyrB26 of insulin. Naive
WT interactionsare shownasblackdashed lines,and thenewly introducedhydrogen-halogen interactions through the3-I-TyrB26mutationare shownasdashed
purple lines. C–F,predictedwater network at theIR/insulin interface aroundTyrB26.C, formationof awater network anchoredby thepara-OHof TyrB26 and the
carbonyl oxygens of Asn-711, Val-712, and Phe-714 (highlighted by green dashed lines) in WT. D–F, reinforcement of the pre-existing water network by
interactions (yellowdashed lines) between the iodine andhydrogenatomsof threewatermolecules labeledWat1,Wat2, andWat3;Wat3bridges the iodine and
para-OH of themodified TyrB26 and the carboxyl oxygen of Asp-12 of the L1 domain (D); andWat1 andWat2 bridge the iodine atom to the carbonyl oxygen of
Val-712 (E and F).
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receptor binding (7–9). Our MD simulations suggest that
enhancement is mediated by quantum chemistry: direct elec-
trostatic effects of the iodine exploiting its 	 -hole and 	
equatorial belt (46). This mechanism envisions that 3-I-TyrB26
switches from an iodo-in conformation (free) to an iodo-out
conformation (IR bound). Testing this proposal will require
higher resolution structures of WT- and iodo-modified hor-
mone-receptor complexes.
Experimental Procedures
Preparation of Insulin Analogs—Analogs were made by tryp-
sin-catalyzed semi-synthesis using insulin fragment des-octa-
peptide(B23–B30)-insulin and modified octapeptides (4). The
fragment was generated via cleavage of human insulin with
trypsin and purified by reverse-phaseHPLC; octapeptides were
synthesized by solid-phase synthesis (82). Formation of a pep-
tide bond between ArgB22 and the synthetic octapeptide was
mediated by trypsin (in a mixed solvent system containing 1,4-
butanediol and dimethylacetamide) (83). Insulin analogs were
purified by preparative reverse-phase C4 HPLC (Higgins Ana-
lytical Inc., Proto 300 C4 10M, 250 20mm), and their purity
assessed by analytical rp-C4HPLC (Higgins C4 5M, 250 4.6
mm). Molecular masses were verified using an Applied Biosys-
tems 4700 proteomics analyzer (matrix-assisted laser-desorp-
tion/ionization time-of-flight mass spectrometry).
Circular Dichroism—Far-ultraviolet CD spectra were
obtained on an AVIV spectropolarimeter equipped with an
automated syringe-driven titration unit. The proteins were
made 50M in 10mMpotassiumphosphate (pH 7.4) and 50mM
KCl. Spectra were obtained from 190–250 nm as described
(84). Thermodynamic stabilities were probed by guanidine
hydrochloride-induced denaturation monitored by CD at 222
nm. Data were fit by non-linear least squares to a two-state
model (85) as described (86).
Receptor Binding Assays—Affinities for IR-B were measured
by a competitive-displacement scintillation proximity assay. This
assay employed solubilized receptorwithC-terminal streptavidin-
binding protein tags purified by sequential wheat germ agglutinin
and StrepTactin-affinity chromatography from detergent lysates
of polyclonal stably transfected 293PEAK cell lines expressing
each receptor. The details of this assay were recently described
(32). Toobtain analog dissociation constants, competitive binding
data were analyzed by non-linear regression (87).
X-ray Crystallography—Crystals of HPLC-purified 3-[iodo-
TyrB26,NleB29]insulin were obtained via hanging-drop vapor
diffusion at 25 °C. 1-l drops containing the protein at 10
mg/ml in 0.02 N HCl were mixed with a 1-l drop of reservoir
buffer containing 0.1 M sodium citrate, 0.08% zinc acetate, and
2% phenol. Drops were suspended over 1ml of reservoir buffer.
A single crystal was transferred to a solution containing 30%
glycerol in themother liquor for flash freezing. Diffraction data
were obtained using an in-house X-ray source consisting of a
Rigaku rotating-anode X-ray generator (MicroMaxTM 007HF)
withVariMax confocal optics, a Saturn 944CCDX-ray detec-
tor, and an X-Stream 2000 cryogenic crystal cooling system
(located at Case Western Reserve University). Data analysis
employed XDS (88). The structure was determined by molecu-
lar replacement using PDB code 1ZNJ as a search model,
followed by iterative refinement and model building using
PHENIX (89) and COOT (90), respectively. The refinement
strategy included both TLS refinement (translation, libration,
and screw rotation) and torsional non-crystallographic symme-
try (NCS) restraints between related chains. Coordinates were
deposited in the Protein Data Bank (code 5EMS).
QM-parameterized MM Calculations—MD simulations
employed CHARMM version c40a1 (91) with the “all-atom”
force fieldCHARMM22 (53) using the correctionmap (CMAP)
potential for the backbone dihedral (
,) to correct for the
-helical bias. To account for electronic anisotropy of ortho-
iodophenol (employed as a model compound for purposes of
MMparametrization), an electrostatic multipole model (MTP)
(54) was obtained for the phenolic ring of TyrB26 and iodophe-
nolic ring of I-TyrB26. The MTP implementation used in this
work is that of Bereau et al. (54), which uses up to quadrupolar
moments on each interaction site (87). Atomic multipoles are
assigned to all heavy atoms (but not the hydrogens). The parame-
trization protocol followed a recently developed strategy that
includes optimization ofmultipolemoments to best represent the
electrostatic potential and van der Waals parameters to correctly
describe experimental solution phase data, including the hydra-
tion free energy of iodophenol (92). MTPs were derived from ab
initio calculations at the MP2/aug-cc-pVDZ (93) level of theory
usingGAUSSIAN09 (94).The iodine atomwas treatedby the aug-
cc-pVDZ-PP basis set with an effective core potential (95). For the
rest of the system, apoint-charge (PC)modelwasused;watermol-
ecules were treated with the TIP3Pmodel (96).
Starting coordinates of the insulin dimers were first taken
from theT2 zinc-free structure ofWT insulin (PDBcode 1DPH,
resolution 1.9Å (97)) and extracted from the R6 structure of the
WT zinc hexamer (PDB 1ZNJ, resolution 2.0 Å), respectively,
and subsequently extended to the present crystal structure of a
3-I-TyrB26 insulin analog. For corresponding simulations of
the variant IR-insulin complex, starting coordinates were
obtained from the lowest energy initial model (see below). The
systems were first minimized by steepest descent for 5  104
steps. The proteins were solvated in TIP3P water molecules
(96) equilibrated at 300 K and 1 atm (within a 52.77Å cubic box
for the dimers and a 93 Å cubic box for the IR-insulin with
sodium and chloride ions added to neutralize the system). The
box was heated from 0 to 300 K for 30 ps, equilibrated for 500
ps, and then subjected to 10 ns of productionMDwith periodic
boundary conditions. The particle mesh Ewald (PME) method
(98) was used for PC-PC interactions, with grid spacing of 1 Å,
a relative tolerance of 106, an interpolation order of 4 for long-
range electrostatics, and a cutoff of 14 Å together with a 12-Å
switching threshold for L-J interactions. Bonds involving
hydrogen were constrained by SHAKE (99).
Because of aromatic ring rotation about the C–C bond
axis, the mono-iodo derivative of [TyrB26]insulin may in prin-
ciple form either 3-I-TyrB26 or 5-I-TyrB26 conformational iso-
mers (with the iodine atom at ring positions 3 or 5; i.e. ortho to
the phenolic hydroxyl group and meta to C). Hence, depend-
ing on the B26 2 angle, isomerization of 3-I-TyrB26 to 5-I-
TyrB26, and vice versa, is possible during the dynamics. Because
the relative stabilities of these conformational isomers were not
known a priori, two independent MD dimer simulations of 20
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ns each were carried out starting from initial 3-I or 5-I B26
conformations, respectively. These simulations began from a T
state crystallographic protomer (PDB code 1DPH (97)) because
the conformation of an insulin monomer in solution resembles
the T state (28, 29).
Rigid-body Calculations—Naive replacement of B26’s H
atoms (atomic radius 1.20 Å and CH bond length 1.08 Å) by
iodine (atomic radius 2.40 Å and CI bond length 2.08 Å) in
positions 3 and 5 was carried out, starting from the coordinates
of T2 zinc-free structure of WT insulin (PDB code 1DPH, res-
olution 1.9 Å (97)). First, the three systems (WT, 3-I, and 5-I )
were energy-minimized by steepest descent for 5  104 steps
using an optimized GBSW (generalized Born with a smoothed
switching function (100, 101)) implicit solvent force field (78).
In a next step, energies from two scans around 1–2 dihedral
angles (20° in each dihedral angle in steps of 1°) were com-
puted, using a PC and an MTP representation for the TyrB26
side chain as follows: (i) a rigid scan, where single point energies
are calculated upon 1–2 rotations, and (ii) a relaxed scan,
where the protein side chains were energy-minimized for 100
steps of steepest descent after each 1–2 rotations.
Quantum-Chemical Calculations—The molecular electro-
static potential (incorporated electron density) from the same
electronic structure calculations was employed for the MTP
parameter fitting as mapped at the 103 e atomic units3
isodensity surface using Gaussview5 (102). All ab initio calcu-
lations were carried out with Gaussian09 (94), and optimized
structures were used. The size of the iodine -hole size was
measured as the angular profile of the ESP intersection line of
the grid and the halogen boundary (defined as a surface of elec-
tron isodensity of 103 e atomic units3) (55). Such ab initio
calculations were undertaken solely for the purpose of param-
eterizing an MM model of the modified insulin. Explicit
QM/MM simulations were not performed.
Modeling of the Variant Hormone-Receptor Complex—To
explore how iodo-TyrB26 might pack within the insulin-IR
complex, the potential environment of the modified ring was
considered in the context of theWT insulin-IR complex (PDB
code 4OGA (39)). Several subsets of residues disordered in
the crystal structure (IR residues Cys-159–Asn-168 and Lys-
265–Gln-276 and insulin residues B28–B30) were included, as
wereN-linkedN-acetylglucosaminemodifications at sites Asn-
16, Asn-25, Asn-111, Asn-215, andAsn-255 (103). An initial set
of 50 models was created, and the structure with lowest empir-
ical energy was selected for MD simulations. A model of the
variant IR complex was constructed in two stages. Prelimi-
nary MD studies of the variant hormone-IR complex were
first performed using a coarse model of the modified side chain
within the GROMACS package (version 4.6.1 (104)) with
OPLS-all atom force field (96, 105) as described below. The
lowest energy model emerging from this simulation then pro-
vided a starting point for QM-parameterized MD as outlined
above. Initial MD simulations of the variant IR complex
exploited an approximate model of 3-I-Tyr in which a virtual
site was placed near the iodine atom to mimic the -hole. This
site’s positionwas determined byminimizing the error of the fit
of the atom-centered charges to the molecular electrostatic
potential for 2-iodo-4-methylphenol, calculated at the HF/6–
311G(d,p) level; the optimal position of the virtual sitewas 1.5Å
from the iodine, co-linear with the C–I bond. Respective partial
charges on the virtual site, iodine and carbon attached to iodine,
were 0.115e, 0.322e, and 0.207e; charges on all other atoms
were adopted from the OPLS-aa parameters for Tyr. Pro-
teins were solvated in a cubic box of TIP4P water molecules
(96); the box extended 10Å beyond any protein atom. Ionizable
residues and protein termini were set in their charged states.
Sodium and chloride ions were added to neutralize the system
at a final ionic strength of 0.10 M. Protein and solvent (including
ions) were coupled separately to a thermal bath at 300 K
employing velocity rescaling (106) with coupling time 1.0 ps.
Pressure was maintained at 1 bar using a Berendsen barostat
(107) with coupling constant 5.0 ps and compressibility 4.5 
105 bar. The time step was 2 fs. Simulations were performed
with a single non-bonded cutoff of 10 Å and neighbor-list
update frequency of 10 steps (20 fs). The PMEmethodmodeled
long-range electrostatics (108); the grid width was 1.2 Å with
fourth-order spline interpolation. Bond lengths were con-
strained using LINCS (109). The MD protocol consisted of an
initialminimizationofwatermolecules, followedby100psofMD
with the protein restrained to permit equilibration of the solvent.
Calculations were continued for 200 ns from the geometries
obtained after initial positionally restrainedMD at a temperature
of 300 K.
Database Deposition—Atomic coordinates of the crystal of
3-[iodo-TyrB26,NleB29]insulin have been deposited in the Pro-
tein Data Bank (code 5EMS).
Supplemental Information—The supplemental Table S1 pro-
vides interaction energies contributing to dimerization. The
supplemental Figs. S1 and S2 provide side-chain dihedral-angle
distributions (1,2). The supplemental Fig. S3 illustrates pre-
dicted packing schemes at the variant dimer interfaces. The
supplemental Fig. S4 illustrates predicted and observed structural
relationships in 3-[iodo-TyrB26]insulin. The supplemental Fig. S5
provides details concerning the alternative (and less favorable)
5-[iodo-TyrB26]insulin dimer interface. The supplemental Fig. S6
depicts water molecules at the variantIR interface.
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FIGURE S1. Dihedral probability distribution functions for the R2 dimers. (A) Structure of 
the R- (α-helix B1-B8; gold) and T (disordered strand B1-B8; cyan) -states of insulin dimer. The 
inset indicates the placement of the invariant GlyB8 as a function of T/R state. Only GlyB8 is 
illustrated. (B and C) Probability distribution functions P(χ1,χ2) for TyrA19, TyrB16, PheB24, 
PheB25, TyrB26 and their dimer related mates (indicated by primes) for  (B) the WT R2 insulin 
dimer, and (C) the 3-iodo-TyrB26 R2 insulin dimer. The distributions were built from 20 ns 
equilibrium MD simulations. The starting dimer structure was taken from a dimer of WT R6 zinc 
 
 
2 
insulin crystal structure (PDB code 1ZNJ). Symbols (box, star, circle) indicate positions in the 
X-ray crystal structure of the 3-I-TyrB26-NleB29–insulin hexamer. 
 
 
 
 
 
 
 
 
FIGURE S2. Dihedral probability distribution functions for the T2 dimers. Probability 
distribution functions P(χ1,χ2) for TyrA19, TyrB16, PheB24, PheB25, TyrB26 and their dimer-related 
mates (indicated by primes) for (A) the WT T2 dimer, and (B) the 3-iodo-TyrB26 T2 dimer. The 
distributions were built from 20 ns of equilibrium MD simulations. The starting dimer structure 
was taken from the T2 zinc-free dimer WT-insulin structure (PDB code 1DPH). Symbols (box, 
star, and circle) indicate positions in the X-ray crystal structure of the 3-I-TyrB26-NleB29-insulin 
hexamer. The side chain of PheB25 is disordered; see main text. 
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FIGURE S3. Packing prediction at the dimer interface. Stereo view of the predicted 
conformational maps of B-chain aromatic residues from 20 ns MD simulation: (A) Packing in the 
WT-, (B) 3-I-TyrB26- and (C) 5-I-TyrB26-insulin dimers. Residues IleA2, ValA3, ValB12, TyrB16, 
PheB24, PheB25, and TyrB26 are shown explicitly (in licorice) together with their dimer-related 
mates. Note the displacement of ValB12 in (C) due to 5-I-TyrB26, compared to WT- and 3-I-TyrB26 
dimers (see main text). The starting dimer structures were taken from the T2 zinc-free dimer WT-
insulin structure (PDB code 1DPH). The iodine atoms are shown as green and yellow spheres for 
3-I-TyrB26- and (C) 5-I-TyrB26 -insulin dimers, respectively. For an overall view, see also Figure 
S4. 
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FIGURE S4. Packing at the dimer interface of 3-I-TyrB26 insulin analog: predicted (A,B) vs. 
crystal structure (C, D) . (A) WT dimer: Residues ValB12, TyrA19, PheB25, and TyrB26 are shown 
(in licorice) together with dimer-related mates. (B) 3-I-TyrB26 dimer: Local interactions with 
residue IleA2, ValA3, GlyB8, LeuB11, ValB12, and TyrA19 are explicitly shown. Iodine atoms are 
shown as green spheres. For a simplified view, see also Figure S3. (C) Stereo view of aromatic-
rich dimer interface. The side chains of TyrB16, PheB24, PheB25 and 3-I-TyrB26 (dark gray sticks) 
are shown in relation to their dimer-related partners and a portion of the anti-parallel β-sheet 
(green; main chain of residues B24-B26 and B24'-B26'). (D) Expanded view of corresponding 
WT and variant B26 side-chain environments in relation to an inter-chain crevice containing 
IleA2, ValA3 and ValB12. Neighboring side chains are as labeled; the sulfur atoms of cystine A7-
B7 are shown as yellow spheres (van der Waals radii). WT coordinates for panels C and D were 
obtained from PDB entry 1ZNJ. 
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FIGURE S5. 5-I-TyrB26-insulin dimerization interface. (A) Structure of 5-I-TyrB26'-insulin 
monomer packing against its related partner illustrates local interaction network between iodine 
on TyrB26' and the backbone oxygen of GlyB20 and the backbone NH of GlyB23. The iodine atom 
is shown as a purple sphere. Only residues interacting with 5-I-TyrB26' are illustrated. Potential 
hydrogen/halogen bonds with I are shown as dashed red lines. (B) Distance probability 
distribution of I(TyrB26)—O(GlyB20') (solid red), I(TyrB26')—O(GlyB20) (dashed red), I(TyrB26)—
HN(GlyB23') (solid green), and I(TyrB26')—HN(GlyB23) (dashed green) from 20 ns of MD 
simulation. The black dashed line at 4.1 Å represents the I—O distance interaction limit. (C) 
Angle probability distribution of C-I(TyrB26)—O(GlyB’20') (solid red), C-I(TyrB26')—O(GlyB20) 
(dashed red), C-I(TyrB26)—HN(GlyB23') (solid green), and C-I(TyrB26')—HN(GlyB23) (dashed 
green) from 20 ns MD simulation. The black dashed line at 127° represents the angular limit for 
I between negative electrostatic region (δ- < 127°) and positive electrostatic region (127° < δ+ < 
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233°). (D) Predicted backbone dihedral angle distributions (φ, ψ) of GlyB20 (upper panels) and 
GlyB23 (lower panels) in the B20-B23 β-turn in WT, 3-I-TyrB26 and 5-I-TyrB26 insulin dimer from 
20 ns of MD simulation, and compared to their dimer-related partners (indicated by primes). The 
starting dimer structure was taken from the T2 Zinc-free dimer WT-insulin structure (PDB code 
1DPH). 5-I-TyrB26 dimer exhibit increased interaction energy along the dimerization interface, 
compared to WT and 3-I-TyrB26, but note that the way iodine interacts with the backbone 
O(GlyB20) leads to its accommodation in a region in the Ramachandran plot that is in principle 
permitted for glycine but which is empirically unfavorable in the context of the native 
conformation of insulin (Nakagawa, S. Hua, Q.-X., Jia, W., Wang, S., Katsoyannis, P.G. and 
Weiss, M.A. (2006) Chiral Mutagenesis of Insulin. CONTRIBUTION OF THE B20-B23 β-TURN TO 
ACTIVITY AND STABILITY. J. Biol. Chem. 281, 22386-96). 
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FIGURE S6. Population of water molecules at the 3-I-TyrB26/µIR interface.  The number N 
of water molecules present in a 3.7, 4.0, 5.0 and 7.0 Å spheres centered around the iodine atom 
within the 3-I-TyrB26/µIR binding pocket during the 1 ns MD simulations. 
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Table S1. Iodo-TyrB26 –induced interaction energies contributing to the dimerization. Interaction 
energies Etotal (sum of van der Waals, EvdW, and electrostatic, Eelec, terms) between TyrB26 and 
neighboring residues calculated for both PC (A) and MTP (B) electrostatics. 
 
 (A) 
Einter   3-I-TyrB26   5-I-TyrB26 
(kcal/mol) EvdW Eelec Etotal EvdW Eelec Etotal 
IleA2 -1.25 -0.06 -1.31 -0.87 -0.02 -0.90 
LeuA3 -0.89 -0.18 -1.07 -0.46 -0.18 -0.65 
GlyB8 -1.52 -0.41 -1.93 -0.98 0.06 -0.92 
LeuB11 -0.94 -0.49 -1.42 -1.13 -0.47 -1.60 
ValB12 -2.45 -0.36 -2.81 -2.38 -0.37 -2.75 
LeuB15 -0.85 0.02 -0.83 -0.91 0.02 -0.89 
ProB28 -3.53 -0.09 -3.63 -3.23 -0.09 -3.32 
TyrB16' -2.34 -0.89 -3.23 -2.60 -0.32 -2.92 
GlyB20' -0.74 -1.77 -2.51 -0.33 -0.04 -0.38 
GlyB23' -1.06 0.84 -0.22 -1.39 0.31 -1.08 
PheB24' -2.62 -0.68 -3.30 -3.47 -0.64 -4.11 
Total -18.19 -4.06 -22.25 -17.75 -1.75 -19.50 
      
 
 
 
(B) 
      Einter   3-I-TyrB26   5-I-TyrB26 
(kcal/mol) EvdW Eelec Etotal EvdW Eelec Etotal 
IleA2 -0.95 -0.47 -1.41 -0.54 -0.39 -0.94 
LeuA3 -0.84 -0.34 -1.17 -0.29 -0.30 -0.59 
GlyB8 -1.31 0.57 -0.73 -0.54 -0.01 -0.55 
LeuB11 -0.94 -0.63 -1.58 -0.66 -0.46 -1.12 
ValB12 -2.39 -0.91 -3.30 -2.04 -0.83 -2.87 
LeuB15 -0.78 -0.41 -1.19 -0.74 -0.38 -1.12 
ProB28 -3.10 -0.89 -3.99 -2.24 -0.78 -3.02 
TyrB16' -2.52 -1.39 -3.91 0.28 -1.96 -1.68 
GlyB20' -0.60 -0.92 -1.52 -0.74 -1.73 -2.47 
GlyB23' -0.96 -0.60 -1.56 -0.73 -2.16 -2.89 
PheB24' -2.95 -0.02 -2.97 -2.15 -0.14 -2.29 
Total -17.32 -6.01 -23.33 -10.39 -9.14 -19.53 
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